Thrombophilia Screening: Not So Straightforward

被引:4
|
作者
Moore, Gary W. [1 ,2 ]
机构
[1] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Haemophilia & Thrombophilia Ctr, Specialist Haemostasis Lab, Cambridge, England
[2] Middlesex Univ, Dept Nat Sci, London, England
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2024年 / 50卷 / 08期
关键词
activated protein C resistance; antithrombin; protein C; protein S; thrombophilia; PROTEIN-S DEFICIENCY; FACTOR-V-LEIDEN; DEEP-VEIN THROMBOSIS; PLASMA COAGULATION INHIBITORS; INDUCED SKIN NECROSIS; GENETIC RISK-FACTOR; C RESISTANCE; DEVELOPMENTAL HEMOSTASIS; PROTHROMBIN MUTATION; C4B-BINDING PROTEIN;
D O I
10.1055/s-0044-1786807
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although inherited thrombophilias are lifelong risk factors for a first thrombotic episode, progression to thrombosis is multifactorial and not all individuals with inherited thrombophilia develop thrombosis in their lifetimes. Consequently, indiscriminate screening in patients with idiopathic thrombosis is not recommended, since presence of a thrombophilia does not necessarily predict recurrence or influence management, and testing should be selective. It follows that a decision to undertake laboratory detection of thrombophilia should be aligned with a concerted effort to identify any significant abnormalities, because it will inform patient management. Deficiencies of antithrombin and protein C are rare and usually determined using phenotypic assays assessing biological activities, whereas protein S deficiency (also rare) is commonly detected with antigenic assays for the free form of protein S since available activity assays are considered to lack specificity. In each case, no single phenotypic assay is capable of detecting every deficiency, because the various mutations express different molecular characteristics, rendering thrombophilia screening repertoires employing one assay per potential deficiency, of limited effectiveness. Activated protein C resistance (APCR) is more common than discrete deficiencies of antithrombin, protein C, and protein S and also often detected initially with phenotypic assays; however, some centres perform only genetic analysis for factor V Leiden, as this is responsible for most cases of hereditary APCR, accepting that acquired APCR and rare F5 mutations conferring APCR will go undetected if only factor V Leiden is evaluated. All phenotypic assays have interferences and limitations, which must be factored into decisions about if, and when, to test, and be given consideration in the laboratory during assay performance and interpretation. This review looks in detail at performance and limitations of routine phenotypic thrombophilia assays.
引用
收藏
页码:1131 / 1152
页数:22
相关论文
共 50 条
  • [31] Thrombophilia screening in renal transplant recipients
    Markau, Silke
    Triebel, Ellen
    Rettkowski, Olaf
    Osten, Bernd
    TRANSPLANT INTERNATIONAL, 2007, 20 : 213 - 213
  • [32] The Case Against Routine Screening for Thrombophilia
    Nicolaides, Andrew
    DM DISEASE-A-MONTH, 2010, 56 (10): : 569 - 573
  • [33] Thrombophilia Screening: Universal, Selected, or Neither?
    Colucci, Giuseppe
    Tsakiris, Dimitrios A.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2017, 23 (08) : 893 - 899
  • [34] Thrombophilia screening in systemic lupus erythematosus
    Sallai, K
    Mohl, A
    Nagy, E
    Gergely, R
    Bodo, I
    CLINICA CHIMICA ACTA, 2005, 355 : S296 - S297
  • [35] Thrombophilia and Hypercoagulation: Risk Assessment and Screening
    Banks-Gonzales, Vanessa Rae
    Ruppert, Susan D.
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2012, 8 (08): : 649 - 655
  • [36] Thrombophilia and Screening in Family Medicine Practice
    Ivanova, Nevena G.
    KONURALP TIP DERGISI, 2023, 15 (03): : 277 - 281
  • [37] Thrombophilia screening in autoimmune hemolytic anemia
    Capecchi, M.
    Cecchi, N.
    Giannotta, J.
    Abbattista, M.
    Novembrino, C.
    Boscolo, M.
    Barcellini, W.
    Fattizzo, B.
    SWISS MEDICAL WEEKLY, 2023, 153 : 28S - 29S
  • [38] Laboratory thrombophilia screening: essentials for hematologists
    Paul A. Kyrle
    memo - Magazine of European Medical Oncology, 2021, 14 : 360 - 363
  • [39] Prenatal screening for thrombophilia: The background and the approach
    James, AH
    Brancazio, LR
    GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2005, 60 (01) : 47 - 57
  • [40] The Not-So-Straightforward Path for Selecting Haploidentical Donors
    Lalli, Peter N.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (03): : 141 - 142